TY - JOUR
T1 - Structural Basis of Nanomolar Inhibition of Tumor-Associated Carbonic Anhydrase IX
T2 - X-Ray Crystallographic and Inhibition Study of Lipophilic Inhibitors with Acetazolamide Backbone
AU - Andring, Jacob T.
AU - Fouch, Mallorie
AU - Akocak, Suleyman
AU - Angeli, Andrea
AU - Supuran, Claudiu T.
AU - Ilies, Marc A.
AU - McKenna, Robert
N1 - Publisher Copyright:
© 2020 American Chemical Society. All rights reserved.
PY - 2020/11/12
Y1 - 2020/11/12
N2 - This study provides a structure-Activity relationship study of a series of lipophilic carbonic anhydrase (CA) inhibitors with an acetazolamide backbone. The inhibitors were tested against the tumor-expressed CA isozyme IX (CA IX), and the cytosolic CA I, CA II, and membrane-bound CA IV. The study identified several low nanomolar potent inhibitors against CA IX, with lipophilicities spanning two log units. Very potent pan-inhibitors with nanomolar potency against CA IX and sub-nanomolar potency against CA II and CA IV, and with potency against CA I one order of magnitude better than the parent acetazolamide 1 were also identified in this study, together with compounds that displayed selectivity against membrane-bound CA IV. A comprehensive X-ray crystallographic study (12 crystal structures), involving both CA II and a soluble CA IX mimetic (CA IX-mimic), revealed the structural basis of this particular inhibition profile and laid the foundation for further developments toward more potent and selective inhibitors for the tumor-expressed CA IX.
AB - This study provides a structure-Activity relationship study of a series of lipophilic carbonic anhydrase (CA) inhibitors with an acetazolamide backbone. The inhibitors were tested against the tumor-expressed CA isozyme IX (CA IX), and the cytosolic CA I, CA II, and membrane-bound CA IV. The study identified several low nanomolar potent inhibitors against CA IX, with lipophilicities spanning two log units. Very potent pan-inhibitors with nanomolar potency against CA IX and sub-nanomolar potency against CA II and CA IV, and with potency against CA I one order of magnitude better than the parent acetazolamide 1 were also identified in this study, together with compounds that displayed selectivity against membrane-bound CA IV. A comprehensive X-ray crystallographic study (12 crystal structures), involving both CA II and a soluble CA IX mimetic (CA IX-mimic), revealed the structural basis of this particular inhibition profile and laid the foundation for further developments toward more potent and selective inhibitors for the tumor-expressed CA IX.
KW - Acetazolamide/chemistry
KW - Binding Sites
KW - Carbonic Anhydrase IX/antagonists & inhibitors
KW - Carbonic Anhydrase Inhibitors/chemistry
KW - Catalytic Domain
KW - Crystallography, X-Ray
KW - Humans
KW - Hydrophobic and Hydrophilic Interactions
KW - Isoenzymes/antagonists & inhibitors
KW - Molecular Dynamics Simulation
KW - Neoplasms/enzymology
KW - Recombinant Proteins/biosynthesis
KW - Structure-Activity Relationship
UR - http://www.scopus.com/inward/record.url?scp=85096152549&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.0c01390
DO - 10.1021/acs.jmedchem.0c01390
M3 - Article
C2 - 33085484
AN - SCOPUS:85096152549
SN - 0022-2623
VL - 63
SP - 13064
EP - 13075
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 21
ER -